Anyone heard of scube3? And other emerging treatments? Research/Science 1/19/2025
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity GT20029 and PP405 the new fin and min that we been waiting for ?
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
community Don’t Get Too Hyped About PP405. We've Seen This Movie Before.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
community Any treatments in development that could theoretically give complete regrowth?
New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.
community (Serious) Updates and discussion, new treatments in development
Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.
community Molecule PP405: A Research Team Backed By Google Ventures Has Discovered One Of The Most Promising Solutions For Hair Loss To Date
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
Related Research
6 / 6 resultsresearch Expression of the Scube3 epidermal growth factor-related gene during early embryonic development in the mouse
This study reports that the mouse Scube3 gene is expressed in various tissues during embryonic development, including the neural tube, limb buds, developing tooth, hair follicle, and skeletal regions.
research Characterization of a mouse Scube3 reporter line
Mouse Scube3 affects teeth, tongue, vibrissae, and eye development, but not facial structure or limb growth.
research Ageratum houstonianum Extract and Agerarin Promote Hair Growth via MAPK/AP-1 Axis-Dependent Upregulation of SCUBE3 in Human Dermal Papilla Cells
In this study, Ageratum houstonianum ethanolic extract and its active component agerarin were found to promote hair growth and follicle elongation by increasing SCUBE3 expression via activation of MAPK–AP-1 signaling in human dermal papilla cells, suggesting potential therapeutic value for treating hair loss.
research Signal Peptide-CUB-EGF-like Domain-Containing Protein 3 (SCUBE3): From Molecule to Therapy
This study found that SCUBE3 protein is upregulated in various cancers, promoting tumor growth and poor outcomes, while suppressing growth in renal cell carcinoma, and may serve as a diagnostic marker and potential therapeutic target for several diseases due to its secreted nature.
research Hedgehog signaling reprograms hair follicle niche fibroblasts to a hyper-activated state
In this study, Hedgehog signaling in dermal papilla fibroblasts was found to accelerate hair growth and induce follicle multiplication in mice via the SCUBE3/TGF-β pathway, with some effects observed in human scalp hair follicles.
research Stem Cell Applications in Human Hair Growth: A Literature Review
This review explores stem cell applications for hair regrowth in alopecia, with no new clinical results, suggesting potential advantages over current FDA-approved treatments.